Verve Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day
27 mars 2023 06h30 HE
|
Verve Therapeutics
BOSTON, March 27, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
Verve Therapeutics Reports New Preclinical Data Demonstrating Potent and Durable Editing of ANGPTL3 Gene with VERVE-201 in Wild-type and LDLR-deficient Non-Human Primates
03 mars 2023 06h30 HE
|
Verve Therapeutics
VERVE-201 Preclinical Data Supports Advancement of Drug Candidate Toward Clinical Development for Homozygous Familial Hypercholesterolemia, with Initiation of Clinical Trial Anticipated in 2024 Data...
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
02 mars 2023 06h30 HE
|
Verve Therapeutics
heart-1 Clinical Trial of VERVE-101 Ongoing in New Zealand and UK; Data from Dose Escalation Cohorts Expected in the Second Half of 2023 VERVE-201 Progressing Through Preclinical Development with...
Verve Therapeutics Announces VERVE-101 Awarded Innovation Passport by the UK MHRA for the Treatment of Heterozygous Familial Hypercholesterolemia
14 févr. 2023 06h30 HE
|
Verve Therapeutics
BOSTON, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene...
Verve Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
03 janv. 2023 16h05 HE
|
Verve Therapeutics
BOSTON, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
Verve Therapeutics to Participate in Upcoming Investor Conferences
11 nov. 2022 06h30 HE
|
Verve Therapeutics
BOSTON, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
Verve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial Results
07 nov. 2022 06h30 HE
|
Verve Therapeutics
VERVE-101 Investigational New Drug Application Placed on Hold by U.S. Food and Drug Administration Dosing Completed in First Dose Cohort of the heart-1 Clinical Trial of VERVE-101 in Patients with...
Verve Therapeutics Announces Publication of VERVE-101 Preclinical Data in Circulation and Presentations at the American Heart Association Annual Meeting
31 oct. 2022 07h00 HE
|
Verve Therapeutics
BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene...
Verve Therapeutics to Participate in Upcoming Investor Conferences
22 sept. 2022 06h30 HE
|
Verve Therapeutics
CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course...
Verve Therapeutics Announces Clearance of Clinical Trial Authorisation Application by the United Kingdom Medicines and Healthcare Products Regulatory Agency for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia
21 sept. 2022 06h30 HE
|
Verve Therapeutics
CAMBRIDGE, Mass., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with...